For years, Woebot was held up as the gold standard for evidence-based mental health chatbots, backed by multiple peer-reviewed randomized controlled trials and FDA Breakthrough Device Designation for a postpartum depression therapeutic. That consumer-facing app no longer exists. As of June 30, 2025, Woebot Health retired its direct-to-consumer product entirely, and the company has pivoted to an enterprise and clinical licensing model that individual consumers can no longer access.
What is Woebot?
Woebot is an AI-powered digital mental health platform originally built around a CBT-based chatbot that delivered evidence-based therapeutic support through a consumer smartphone app. Developed by Woebot Health and grounded in Cognitive Behavioral Therapy, Interpersonal Psychotherapy, and Dialectical Behavior Therapy techniques, it served an estimated 1.5 million users before the company shut down the direct-to-consumer app on June 30, 2025. Woebot Health's founder cited the cost and difficulty of meeting FDA marketing authorization requirements, combined with the company's desire to incorporate newer large language models the FDA hasn't yet established a regulatory framework for, as central reasons for the shutdown. The company has since pivoted entirely to an enterprise model, partnering with health systems, insurance payers, and employers to integrate its clinically studied approach into existing care pathways rather than offering it as a standalone consumer product.
Key features
CBT-Based Therapeutic Framework
Built on Cognitive Behavioral Therapy, Interpersonal Psychotherapy, and Dialectical Behavior Therapy techniques, forming the clinical foundation of Woebot's conversational approach.
Peer-Reviewed Clinical Validation
Backed by more than 30 peer-reviewed publications, including randomized controlled trials covering depression, anxiety, postpartum depression, substance use disorder, and adolescent mental health.
FDA Breakthrough Device Designation
Received FDA Breakthrough Device Designation in 2021 for WB001, a postpartum depression digital therapeutic combining CBT and interpersonal psychotherapy techniques.
Enterprise and Health System Integration
Now operates exclusively through partnerships with health systems, payers, and employers rather than a direct-to-consumer app, integrating into existing clinical and benefits infrastructure.
Clinical Research Licensing
Available to researchers conducting clinical studies through direct licensing arrangements with Woebot Health.
Relational Agent Design
Designed as a digital companion aiming to form a therapeutic bond with users through 24/7 chat-based support, a design philosophy carried over from its consumer app era.
Pros
- Genuinely one of the most clinically validated AI mental health platforms in its category, with a substantial body of peer-reviewed research behind its therapeutic approach
- FDA Breakthrough Device Designation reflects real regulatory recognition of its postpartum depression digital therapeutic specifically
- Enterprise pivot allows integration into existing clinical and benefits infrastructure at health systems and payers, potentially reaching populations at scale
- The underlying clinical evidence base remains a genuine differentiator compared to many newer, less clinically studied AI companion apps
Cons
- The consumer-facing app that most reviews and comparisons reference no longer exists; it was permanently retired on June 30, 2025, with all account data anonymized by July 31, 2025
- Individual consumers cannot currently access Woebot in any form; it's available only through enterprise, health system, and payer partnerships
- No public pricing exists, since Woebot now uses fully custom, contact-based enterprise pricing rather than any consumer subscription
- The shutdown reflects broader difficulty scaling B2C mental health apps under FDA regulatory constraints, a risk worth weighing when evaluating any AI mental health tool's long-term availability
Pricing
Woebot no longer offers any consumer pricing, since the direct-to-consumer app was permanently shut down on June 30, 2025. The platform now operates exclusively on contact-based enterprise pricing for health systems, payers, and employer partnerships, with no published rate card. Organizations interested in Woebot Health's enterprise offering, or researchers interested in licensing the platform for clinical studies, must contact Woebot Health directly to discuss terms.
Best for
Woebot is best suited to health systems, insurance payers, and employers wanting to integrate a clinically validated, CBT-based digital mental health tool into existing care pathways or benefits packages, and to clinical researchers seeking a peer-reviewed, RCT-validated platform for study use. It fits AI Healthcare workflows centered on scaling behavioral health access within an institutional context. Individual consumers looking for a personal AI mental health companion should look elsewhere, since Woebot is no longer available as a direct-to-consumer product in any form.
Use cases
- Integrating a clinically validated CBT-based tool into a health system's existing behavioral health pathway
- Offering a peer-reviewed digital mental health resource as part of an employer benefits package
- Supporting primary care providers with an adjunctive mental health tool for patients showing signs of depression or anxiety
- Conducting clinical research using a platform with an established evidence base and prior FDA recognition
- Scaling behavioral health access for a payer's covered population through an institutional partnership
Supported platforms
- Woebot's current enterprise offering is delivered through institutional partnerships with health systems, payers, and employers rather than a standalone consumer app, since the original smartphone application was retired in June 2025.
Languages
- Woebot's therapeutic content and conversational interface were primarily available in English during its consumer app era, and its current enterprise offering continues to be English-language focused.
Integrations
- Woebot integrates into health system and payer partnerships rather than offering standard consumer-facing app integrations, reflecting its current enterprise-only positioning.
Things to consider
- If you're specifically looking for a consumer AI mental health companion, understand that Woebot is not currently available in that form, since the direct-to-consumer app was permanently retired in June 2025 and no relaunch has been announced. Organizations evaluating Woebot for enterprise integration should factor in that pricing is entirely custom and requires a direct sales conversation, with no published starting rate. When comparing AI mental health tools generally, weighing a company's strategic alignment, whether the product itself is the primary business or a feature inside an enterprise-focused company, alongside clinical evidence can help gauge long-term product durability.
How the tool compares
For consumers specifically seeking an AI companion for everyday emotional support, Elomia remains an active, subscription-based consumer option, unlike Woebot's current enterprise-only availability. Among clinically validated digital therapeutics still serving consumers directly, newer entrants have stepped into the space Woebot vacated, some now claiming FDA Breakthrough Device Designation of their own alongside broader peer-reviewed publication counts. Health systems and payers specifically wanting Woebot's original clinical evidence base and CBT framework should pursue the enterprise partnership route directly; individual consumers need a different, currently available consumer app instead.
AIToolister verdict
Quick Answers
- Is it free? No — Woebot has no consumer offering or pricing; it uses fully custom enterprise pricing. - Is it worth it? Only relevant for institutional buyers now, since the consumer app was permanently shut down in 2025. - Who should use it? Health systems, payers, employers, and clinical researchers pursuing an enterprise partnership. - Best alternative: Elomia for consumers wanting an actively available AI mental health companion app.
Woebot's clinical evidence base remains genuinely impressive, and its pivot to enterprise partnerships means that evidence base is still being put to use at the health system and payer level rather than disappearing entirely. For individual consumers, though, the practical reality is that Woebot the app no longer exists, and anyone researching it in 2026 should understand they're evaluating an enterprise partnership model, not a product they can personally download and subscribe to. For institutional buyers with the right use case, it remains one of the more clinically credentialed options in digital mental health; for individual consumers, it's simply not accessible anymore.
Decision Summary
- Health system, payer, or employer exploring digital mental health partnerships: Worth a direct conversation with Woebot Health - Individual consumer wanting a personal AI mental health companion: Not available — consider Elomia or a similar active consumer app - Researcher needing a clinically validated platform for a study: Contact Woebot Health about licensing terms - Evaluating long-term product durability of AI mental health apps generally: Consider company strategic alignment alongside clinical evidence
Frequently asked questions
- Can I still download and use the Woebot app?
No, the Woebot consumer app was permanently retired on June 30, 2025. New accounts can no longer be created, existing accounts are inaccessible, and all account data was anonymized as of July 31, 2025.
- Why did Woebot shut down its consumer app?
Woebot's founder cited the cost and difficulty of meeting FDA marketing authorization requirements, along with the company's desire to incorporate newer large language models that the FDA hasn't yet established a clear regulatory pathway for, as central reasons behind the shutdown.
- Is Woebot still available in any form?
Yes, Woebot Health continues to operate through enterprise partnerships with health systems, payers, and employers, along with clinical research licensing, though it's no longer available as a direct-to-consumer product.
- How much does Woebot cost for an enterprise partnership?
Woebot uses fully custom, contact-based enterprise pricing with no published rate card. Organizations must contact Woebot Health directly to discuss partnership terms.
- What happened to my data if I used the Woebot app before it shut down?
Woebot allowed users to download their conversation history before the shutdown deadline, and the company pledged that all remaining account data would be anonymized after July 31, 2025, removing any personally identifying information.